Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
New Strong Sell Stocks for September 26th
09:47am, Monday, 26'th Sep 2022
EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.
New Strong Sell Stocks for September 9th
10:36am, Friday, 09'th Sep 2022 Zacks Investment Research
EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.
New Strong Sell Stocks for September 9th
08:17am, Friday, 09'th Sep 2022
EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.
New Strong Sell Stocks for September 1st
10:43am, Thursday, 01'st Sep 2022 Zacks Investment Research
CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List on September 1, 2022.
New Strong Sell Stocks for September 1st
08:33am, Thursday, 01'st Sep 2022
CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List on September 1, 2022.
Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
08:05pm, Tuesday, 30'th Aug 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executiv
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?
04:23pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation
04:53pm, Thursday, 18'th Aug 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal C
Eli Lilly's (LLY) Potential New Products Key to Growth
02:15pm, Monday, 15'th Aug 2022 Zacks Investment Research
Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript
04:00pm, Tuesday, 09'th Aug 2022 The Motley Fool
EGRX earnings call for the period ending June 30, 2022.
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates
12:15pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals, Inc's (EGRX) CEO Scott Tarriff on Q2 2022 Results - Earnings Call Transcript
11:19am, Tuesday, 09'th Aug 2022
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – President and Chief Exec
Eagle Pharmaceuticals Reports Second Quarter 2022 Results
10:50am, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
• Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant
10:45am, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected i
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates
09:47am, Tuesday, 09'th Aug 2022
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
